Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy
This is a clinical observation of a patient treated for metastatic head and neck cancer with mesenchymal stem cells mediated prodrug gene therapy. The cells were applied intravenously. We did not observe any therapeutic effect. However, a temporal bicytopenia was observed. Key Words: metastatic head...
Gespeichert in:
| Datum: | 2015 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2015
|
| Schriftenreihe: | Experimental Oncology |
| Schlagworte: | |
| Online Zugang: | http://dspace.nbuv.gov.ua/handle/123456789/145561 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Zitieren: | Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy / J. Lakota, K. Gocarova, S. Spanik // Experimental Oncology. — 2015. — Т. 37, № 4. — С. 298. — Бібліогр.: 1 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-145561 |
|---|---|
| record_format |
dspace |
| spelling |
irk-123456789-1455612019-01-24T01:23:20Z Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy Lakota, J. Gocarova, K. Spanik, S. Short communications This is a clinical observation of a patient treated for metastatic head and neck cancer with mesenchymal stem cells mediated prodrug gene therapy. The cells were applied intravenously. We did not observe any therapeutic effect. However, a temporal bicytopenia was observed. Key Words: metastatic head and neck cancer, therapeutic stem cells, blood counts. 2015 Article Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy / J. Lakota, K. Gocarova, S. Spanik // Experimental Oncology. — 2015. — Т. 37, № 4. — С. 298. — Бібліогр.: 1 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/145561 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Short communications Short communications |
| spellingShingle |
Short communications Short communications Lakota, J. Gocarova, K. Spanik, S. Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy Experimental Oncology |
| description |
This is a clinical observation of a patient treated for metastatic head and neck cancer with mesenchymal stem cells mediated prodrug gene therapy. The cells were applied intravenously. We did not observe any therapeutic effect. However, a temporal bicytopenia was observed. Key Words: metastatic head and neck cancer, therapeutic stem cells, blood counts. |
| format |
Article |
| author |
Lakota, J. Gocarova, K. Spanik, S. |
| author_facet |
Lakota, J. Gocarova, K. Spanik, S. |
| author_sort |
Lakota, J. |
| title |
Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy |
| title_short |
Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy |
| title_full |
Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy |
| title_fullStr |
Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy |
| title_full_unstemmed |
Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy |
| title_sort |
treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2015 |
| topic_facet |
Short communications |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/145561 |
| citation_txt |
Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy / J. Lakota, K. Gocarova, S. Spanik // Experimental Oncology. — 2015. — Т. 37, № 4. — С. 298. — Бібліогр.: 1 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT lakotaj treatmentofmetastaticheadandneckcancerwithmesenchymalstemcellscombinedwithprodruggenetherapy AT gocarovak treatmentofmetastaticheadandneckcancerwithmesenchymalstemcellscombinedwithprodruggenetherapy AT spaniks treatmentofmetastaticheadandneckcancerwithmesenchymalstemcellscombinedwithprodruggenetherapy |
| first_indexed |
2025-07-10T21:57:39Z |
| last_indexed |
2025-07-10T21:57:39Z |
| _version_ |
1837298803556745216 |
| fulltext |
298 Experimental Oncology 37, 298–298, 2015 (December)
TREATMENT OF METASTATIC HEAD AND NECK CANCER
WITH MESENCHYMAL STEM CELLS COMBINED WITH PRODRUG
GENE THERAPY
J. Lakota1,2,*, K. Gocarova3, S. Spanik3
1Laboratory of Molecular Oncology, Cancer Research Institute, Slovak Academy of Sciences,
Bratislava 83391, Slovakia
2 Center for Cell Therapy and Regenerative Medicine, St. Elizabeth Cancer Institute, Bratislava 81250, Slovakia
3Department of Medical Oncology, St. Elizabeth Cancer Institute, Bratislava 81250, Slovakia
This is a clinical observation of a patient treated for metastatic head and neck cancer with mesenchymal stem cells mediated pro-
drug gene therapy. The cells were applied intravenously. We did not observe any therapeutic effect. However, a temporal bicytope-
nia was observed.
Key Words: metastatic head and neck cancer, therapeutic stem cells, blood counts.
A 41 years old male patient with squamous carcinoma
of the tongue (T2N0M0) refused any adjuvant chemo-
therapy after the surgery. He developed lung metastases
9 months after the second surgery for local relapse.
After an approval of the Ministry of Health of the Slovak
Republic, on day −2 he was admitted to the hospital.
Infusion of Ancotil (2.5 g flucytosine/250 ml solution)
started on day −1 bid 24 hours before the administration
of therapeutic stem cells (TSC), and continued for 7 days.
On day 0 the patient received 60×106 allogenic TSC
intravenously. The therapeutic adipose tissue-derived
mesenchymal stem cells were prepared as described
previously [1]. There were no adverse effects during and
6 h after the administration. 18 hours after the intravenous
administration of the TSC, the patient developed fever
(39.0 °C) with no signs of circulation instability. The fever
resolved after antipyretics. There were no signs of any mi-
crobial infection. The following days the patient remained
afebrile. Due to a sudden drop of white blood cells he re-
ceived an oral antibacterial and antimycotic prophylaxis.
On the day +6 he was discharged from the hospital with
almost normalized blood counts. On day +18 during the
outpatient control he was doing well. His blood counts
(except mild anemia) were normal (Table). The CT scan
performed on day +6 showed no difference in the size
or density of his pulmonary metastases compared to the
CT scan on day −1. On the day +40 there were signs
of a progression of the metastases on the CT scan.
Table. Blood counts of the patient during and after the therapy
Day Leukocytes
(×10-12/l)
Neutrophils
(×10-12/l)
Erythrocytes
(×10-15/l) Hb (g/l) Plt
(×10-14/l)
–2 6.88 4.86 4.41 134 179
0 5.82 3.98 3.71 119 150
+1 4.06 3.41 3.80 119 119
+2 1.99 1.00 3.41 112 100
+3 2.89 1.58 3.72 117 115
+4 3.50 2.16 3.72 115 122
+5 4.50 2.98 3.79 118 129
+6 4.29 2.63 3.89 121 132
+18 6.57 4.66 4.06 125 191
The treatment with TSC of this patient highlighted two
points: 1) There was no sign of any therapeutic effect after
intravenous (not local, i.e. intratumoral) administration
of the TSC. 6 days after the administration the metastatic
process did not show any signs of regression. Moreover,
after 40 days after the treatment there was a progression
of the metastases. 2) After the intravenous administra-
tion the TSC are pro bably “homing” in the bone marrow
despite the adipose tissue origin. Even a rather low cell
count (60•106) was able to cause grade 2 (3) thrombope-
nia (neutropenia). It should be noted that this patient did
not receive any systemic chemotherapy in the past. The
observed bicytopenia with a nadir occurred 48 h after the
administration of TSC (with concomitant prodrug adminis-
tration). Therefore it should be carefully considered when
a medical team decides to use the intravenous route.
ACKNOWLEDGEMENT
We are indebted prof. C. Altaner and his team from
the Center for Cell Therapy and Regenerative Medicine
for preparing the TSC.
REFERENCE
1. Kucerova L, Altanerova V, Matuskova M, et al. Adi-
pose tissue-derived human mesenchymal stem cells mediated
prodrug cancer gene therapy. Cancer Res 2007; 67: 6304–13.
Submitted: September 24, 2015.
*Correspondence: E-mail: jan.lakota@savba.sk
Abbreviation used: TSC – therapeutic stem cells.
Exp Oncol 2015
37, 4, 298
Copyright © Experimental Oncology, 2015
|